このアイテムのアクセス数: 24

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
s13075-025-03541-8.pdf1.47 MBAdobe PDF見る/開く
タイトル: Predicting rheumatoid arthritis progression from seronegative undifferentiated arthritis using machine learning: a deep learning model trained on the KURAMA cohort and externally validated with the ANSWER cohort
著者: Fujii, Takayuki  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-6556-1226 (unconfirmed)
Murata, Koichi
Kohjitani, Hirohiko
Onishi, Akira
Murakami, Kosaku  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0001-5981-4648 (unconfirmed)
Tanaka, Masao
Yamamoto, Wataru
Nagai, Koji
Yoshikawa, Ayaka
Etani, Yuki
Okita, Yasutaka
Yoshida, Naofumi
Amuro, Hideki
Okano, Tadashi
Ueda, Yo
Okano, Takaichi
Hara, Ryota
Hashimoto, Motomu
Morinobu, Akio
Matsuda, Shuichi
発行日: 26-Mar-2025
出版者: Springer Nature
BMC
誌名: Arthritis Research & Therapy
巻: 27
号: 1
論文番号: 65
抄録: Background: Undifferentiated arthritis (UA) often develops into rheumatoid arthritis (RA), but predicting disease progression from seronegative UA remains challenging because seronegative RA often does not meet the classification criteria. This study aims to build a machine learning (ML) model to predict the progression from seronegative UA to RA using clinical and laboratory parameters. Methods: KURAMA cohort (training dataset) and ANSWER cohort (validation dataset) were utilized. Patients with seronegative UA were selected based on specific inclusion and exclusion criteria. Clinical and laboratory parameters, including demographic data, acute phase reactants, autoantibodies, and physical examination findings, were collected. Various ML models, including a Feedforward Neural Network (FNN), were developed and compared. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), sensitivity, and other metrics. SHapley Additive exPlanations (SHAP) values were computed to interpret the importance of variables. Results: KURAMA cohort included 210 patients with seronegative UA, of whom 57 (27.1%) progressed to RA. The FNN model demonstrated the highest predictive performance with an AUC of 0.924 and a sensitivity of 80.7% in the training dataset. Validation with ANSWER cohort (140 patients; 32.1% progressed to RA) showed an AUC of 0.777, sensitivity of 77.8%. MMP-3 had the highest impact on the model. Conclusions: The FNN model exhibited robust performance in predicting the progression of RA from seronegative UA and maintained substantial sensitivity in an independent validation cohort. This model using only clinical and laboratory parameters has potential for predicting RA progression in patients with seronegative UA.
著作権等: © The Author(s) 2025
This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
URI: http://hdl.handle.net/2433/293108
DOI(出版社版): 10.1186/S13075-025-03541-8
PubMed ID: 40140918
出現コレクション:学術雑誌掲載論文等

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス Creative Commons